由於糖尿病管理的進步以及對快速、準確檢測方法的需求不斷增加，即時診斷 HbA1c 檢測市場正在快速成長。 HbA1c 測試對於監測糖尿病患者的長期血糖水平至關重要，它能夠提供即時結果，從而改變醫療保健提供者管理糖尿病的方式。最近的技術創新，例如便攜式、易於使用的設備的開發以及用於數據分析的數位平台的集成，使得這些測試更加容易獲得和高效。顯著的進步包括能夠以最少的樣本要求提供更快結果的系統，例如羅氏和西門子醫療等公司提供的系統。此外，主要參與者之間的合作，例如 HemoCue 與 Novo Nordisk 的合作，正在擴大中低收入國家獲得即時診斷服務的機會，從而改善全球醫療保健結果。糖尿病盛行率的上升也推動了市場的成長，特別是在北美和亞太等醫療保健服務和意識不斷提高的地區。隨著研發投入的增加和對以患者為中心的護理的日益關注，預計即時診斷 HbA1c 檢測市場將繼續擴大，為全球更好的糖尿病管理做出貢獻。
Frequently Asked Questions
The market is segmented based on Global Point-of-Care Hba1c Testing Market Segmentation, By Product (Instruments and Consumables), Technology (ION– Exchange HPCL, Enzymatic Assay, Affinity Binding Chromatography, and Turbidimatric Inhibition Immunoassay), End-Users (Hospitals, Clinics, Ambulatory Surgery Centres, and Others) – Industry Trends and Forecast to 2032
.
The Global Point Of Care Hba1c Testing Market size was valued at USD 670.17 USD Million in 2024.
The Global Point Of Care Hba1c Testing Market is projected to grow at a CAGR of 5.59% during the forecast period of 2025 to 2032.
The major players operating in the market include Bio Rad laboratoriesInc. , Arkray INC, A menarini group,F. Hoffmann-La Roche Ltd, Siemens Healthcare GmbH , Hemocue Ab, Trinity Biotech , Pts Digonstic, Siemens healthcare gmbh, Alera inc, Danaher, Sugentech,Tech inc, Getein biotech I.N.C, Bio Merieux India Pvt ltd, EKF Diagnostic.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
